Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Half-Life of Sermorelin: Comparison with Other GH Secretagogues

Sermorelin (GRF 1-29) 10–20 minutes GHRH receptor agonist; triggers pulsatile GH release from pituitary Once daily (bedtime preferred) Shortest half-life but effective for mimicking natural GH pulses. Best for preserving physiological rhythm and receptor sensi

This comparison does not assign a generated winner or score.

  • Sermorelin (GRF 1-29)
  • 10–20 minutes
  • GHRH receptor agonist; triggers pulsatile GH release from pituitary
  • Once daily (bedtime preferred)
  • Shortest half-life but effective for mimicking natural GH pulses. Best for preserving physiological rhythm and receptor sensitivity.
  • CJC-1295 (no DAC)
  • ~30 minutes
  • GHRH receptor agonist; similar to sermorelin but slightly more stable
  • 1–3 times per week
  • Marginally longer half-life than sermorelin. Allows less frequent dosing while maintaining pulsatile pattern.
  • CJC-1295 with DAC
  • 6–8 days
  • GHRH receptor agonist with albumin binding via Drug Affinity Complex
  • Once per week
  • Extended half-life produces continuous low-level GH elevation rather than pulses. May cause receptor desensitization over time.
  • Ipamorelin
  • ~2 hours
  • Ghrelin receptor agonist (growth hormone secretagogue receptor, GHSR)
  • 1–2 times daily
  • Longer functional window than sermorelin. Often stacked with GHRH analogues for synergistic effect.
  • GHRP-2
  • ~30 minutes (plasma)
  • Ghrelin receptor agonist; stimulates appetite and GH release
  • 1–3 times daily
  • Similar kinetics to sermorelin but works through different receptor. Appetite stimulation limits use in some populations.
  • Sermorelin's position in this comparison highlights the trade-off between half-life and receptor dynamics. Longer half-life compounds reduce injection frequency but may compromise the pulsatile secretion pattern that defines healthy GH physiology. For researchers prioritizing circadian alignment and long-term receptor health, sermorelin's brief plasma presence is a feature, not a limitation.
More references

Related material